Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18966535 | 0.97 | NAMPT (0.33) | NAMPTUSP2HSD17B10 | |
| SCHEMBL18966629 | 0.93 | NAMPT (0.31) | NAMPT | |
| SCHEMBL18966611 | 0.93 | NAMPT (0.32) | NAMPT | |
| SCHEMBL18966681 | 0.93 | — | — | |
| SCHEMBL18966639 | 0.93 | NAMPT (0.31) | NAMPTUSP2HSD17B10 | |
| SCHEMBL18966683 | 0.92 | NAMPT (0.32) | NAMPTUSP2HSD17B10 | |
| SCHEMBL18957221 | 0.91 | TRPA1 (0.33) | HSD17B10 | |
| SCHEMBL18957222 | 0.91 | TRPA1 (0.33) | HSD17B10 | |
| SCHEMBL18966855 | 0.91 | MTNR1A (0.34) | NAMPT | |
| SCHEMBL18966653 | 0.91 | PRKCB (0.32) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | NAMPT 1369/4885USP2 869/4885HSD17B10 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.